构建智能化的CAR T细胞疗法：克服当前挑战的路径。
Building smart CAR T cell therapies: The path to overcome current challenges.
发表日期：2023 Sep 13
作者：
Qi Cai, Sarah Warren, Violena Pietrobon, Markus Maeurer, Lei S Qi, Timothy K Lu, Marc J Lajoie, David Barrett, David F Stroncek, Francesco M Marincola
来源：
CANCER CELL
摘要：
癌症的细胞免疫治疗（Adoptive Cell Therapy, ACT）的成功实施需要全面解决生物学和实际问题。然而，这种方法往往被忽视，导致ACT的潜力与实际效果之间存在差距。我们总结了创建“理想”ACT产品的最有希望的技术策略，重点关注嵌合抗原受体（Chimeric Antigen Receptor, CAR）工程细胞。由于大多数癌症对有效的ACT有共同要求，我们在这里概述的内容可能具有更广泛的影响。Copyright © 2023 Elsevier Inc. All rights reserved.
Successful implementation of adoptive cell therapy (ACT) of cancer requires comprehensively addressing biological and practical challenges. This approach has been largely overlooked, resulting in a gap between the potential of ACT and its actual effectiveness. We summarize the most promising technical strategies in creating an "ideal" ACT product, focusing on chimeric antigen receptor (CAR)-engineered cells. Since many requirements for effective ACT are common to most cancers, what we outline here might have a broader impact.Copyright © 2023 Elsevier Inc. All rights reserved.